Results 61 to 70 of about 1,268 (176)

Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod

Frontiers in Neurology
IntroductionTemporal lobe epilepsy (TLE) is a significant clinical phenotype of anti-glutamic acid decarboxylase (GAD)-associated disease, which is characterized by disturbances in GABAergic inhibitory neurotransmission.
Min Chen, Zhuajin Bi, Wenzhong Kang, Ruihan Liu, Liu Hongbo, Yan Jiang, Qun Wang, Qun Wang, Qun Wang   +8 more
doaj   +1 more source

Comparing Efficacy and Safety of Various Monoclonal Antibodies in Myasthenia Gravis: A Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials

Brain and Behavior, Volume 16, Issue 6, June 2026.
ROZ 10 mg/kg ranked best for reducing MG‐ADL. BAT 680 mg significantly reduced QMG and ranked best. BAT 340 mg had the highest probability of reducing the MGC score. ECU significantly decreased MG‐QoL 15r and ranked best. BEL 10 mg/kg had the highest likelihood of reducing adverse events.
Muhammad Hassan Waseem, Zain ul Abideen, Minahil Iqbal, Saniya Ishtiaq, Pawan Kumar Thada, Adam A. Dmytriw   +5 more
wiley   +1 more source

Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China

Annals of Clinical and Translational Neurology
Objective Efgartigimod, a neonatal Fc receptor antagonist, facilitates antibody degradation including pathogenic IgGs. The ADAPT study demonstrated the tolerability and efficacy of efgartigimod in the treatment of generalized myasthenia gravis (gMG ...
Sushan Luo, Qilong Jiang, Wenshuang Zeng, Qinzhou Wang, Zhangyu Zou, Yanyan Yu, Daojun Hong, Quantao Zeng, Song Tan, Zhouao Zhang, Yong Zhang, Xiuming Guo, Jing Chen, Zhongyan Zhao, Shixiong Huang, Jianquan Shi, Ying Chen, Lei Du, Chong Yan, Jianying Xi, Jie Song, Chongbo Zhao, the Chinese Myasthenia Gravis Collaborating Group (CMGCG)   +22 more
doaj   +1 more source

Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng, Yuting Jiang, Nairong Xie, Wenjia Zhu, Hai Chen, Yaye Wang, Haoran Liu, Qinyao Liu, Congwen Lv, Yu Qian, Yan Lu, Li Di, Min Wang, Min Xu, Xinmei Wen, Bingchuan Xie, Yuwei Da   +16 more
wiley   +1 more source

Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
In this exploratory study, no statistically significant differences in effectiveness, safety, or cost were observed between EFG and LPE, nor between RACT and oral immunosuppressants for pre‐thymectomy preparation in MG. These findings are hypothesis‐generating and warrant prospective validation.
Qian Zhou, Ting He, Yuanda Cheng, Kangzhi Chen, Yuzhen Ouyang, Xiaohua Dong, Guanzhong Shi, Zeyi Wen, Huan Yang   +8 more
wiley   +1 more source

Efgartigimod alfa for the treatment of primary immune thrombocytopenia

Therapeutic Advances in Hematology, 2023
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia. Most patients with ITP have antiplatelet antibodies of the immunoglobulin G (IgG) subtype which through interaction with platelet and megakaryocyte glycoproteins result in increased platelet destruction and inhibition of platelet ...
openaire   +3 more sources

Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison [PDF]

Introduction!#!Efgartigimod and ravulizumab, both approved for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG), have not been directly compared. This paper assessed comparative effects of efgartigimod
van Steen, Cécile, Hagenacker, Tim, Celico, Lorenzo, Smith, Gordon, Bodicoat, Danielle, Iannazzo, Sergio, Spaepen, Erik, Ruck, Tobias, De Francesco, Maria, Meuth, Sven G.   +9 more
core   +1 more source

Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders

Orphanet Journal of Rare Diseases
Background Neuromyelitis Optica Spectrum Disorders (NMOSD) comprise a group of autoimmune-mediated, inflammatory, demyelinating central nervous system diseases caused by aquaporin-4 (AQP4) IgG autoantibodies.
Wenjing Yang, Pei Chen, Jiaxuan Guo, Huiyu Feng, Xin Huang   +4 more
doaj   +1 more source

Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience [PDF]

Background: We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) in the UK.
Sathasivam, S., Howard, Robin S, Ambrose, Philip, Hill, M., Norwood, F., Jacob, Saiju, Howard, R.S., Viegas, Stuart, Norwood, Fiona, Moniz Dionísio, J., Leite, M.I., Kullmann, Dimitri, Pritchard, Jane, Farrugia, Maria Elena, Miller, James, Pritchard, J., Pinto, Ashwin, Hewamadduma, C., Spillane, J., Hill, Marguerite, Sathasivam, Sivakumar, Kullmann, D., Riswick, T., Moniz Dionísio, Joana, Garcia-Reitboeck, P., Jacob, S., Garcia-Reitboeck, Pablo, Farrugia, M.E., Hewamadduma, Channa, Thambirajah, Narmathey, Thambirajah, N., Leite, Maria Isabel, Riswick, Thomas, Spillane, Jennifer, Viegas, S., Ambrose, P., Burke, Georgina, Burke, G., Miller, J., Pinto, A.   +39 more
core   +5 more sources

Short-term treatment of CIDP with efgartigimod: a case series in China

Frontiers in Immunology
ObjectiveChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of autoimmune neuropathy with treatment challenges due to the limitations of standard of care therapies.
Chong Sun, Chong Sun, Chong Sun, Jianian Hu, Jianian Hu, Jianian Hu, Yanyin Zhao, Yanyin Zhao, Yanyin Zhao, Yongsheng Zheng, Yongsheng Zheng, Yongsheng Zheng, Quanhua Meng, Sushan Luo, Sushan Luo, Sushan Luo, Kai Qiao, Kai Qiao, Kai Qiao, Jian Sun, Jian Sun, Jian Sun, Jiahong Lu, Jiahong Lu, Jiahong Lu, Jie Lin, Jie Lin, Jie Lin, Chongbo Zhao, Chongbo Zhao, Chongbo Zhao   +30 more
doaj   +1 more source